Updated treatment recommendation for systemic treatment: from the ESMO oncogene-addicted metastatic NSCLC Living Guideline†

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Original languageEnglish
JournalAnnals of Oncology
DOIs
Publication statusE-pub ahead of print - 21 Jun 2025

Keywords

  • BRAF mutation
  • EGFR mutation
  • KRAS G12C mutation
  • guideline
  • metastatic oncogene-addicted non-small cell lung cancer (mNSCLC)
  • treatment

Cite this